204 related articles for article (PubMed ID: 22859720)
1. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
Stevenson L; Allen WL; Turkington R; Jithesh PV; Proutski I; Stewart G; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
Clin Cancer Res; 2012 Oct; 18(19):5412-26. PubMed ID: 22859720
[TBL] [Abstract][Full Text] [Related]
2. Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
Tong M; Zheng W; Lu X; Ao L; Li X; Guan Q; Cai H; Li M; Yan H; Guo Y; Chi P; Guo Z
Oncotarget; 2015 Dec; 6(38):41216-27. PubMed ID: 26515599
[TBL] [Abstract][Full Text] [Related]
3. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.
Xie T; Geng J; Wang Y; Wang L; Huang M; Chen J; Zhang K; Xue L; Liu X; Mao X; Chen Y; Wang Q; Dai T; Ren L; Yu H; Wang R; Chen L; Chen C; Chu X
Oncotarget; 2017 Jan; 8(5):8574-8589. PubMed ID: 28051999
[TBL] [Abstract][Full Text] [Related]
5. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693
[TBL] [Abstract][Full Text] [Related]
6. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
[TBL] [Abstract][Full Text] [Related]
7. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
8. Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters.
Kiezun J; Kiezun M; Krazinski BE; Paukszto L; Koprowicz-Wielguszewska A; Kmiec Z; Godlewski J
Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551197
[TBL] [Abstract][Full Text] [Related]
9. The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma.
Sugimoto T; Seki N; Shimizu S; Kikkawa N; Tsukada J; Shimada H; Sasaki K; Hanazawa T; Okamoto Y; Hata A
Genes Chromosomes Cancer; 2009 Feb; 48(2):132-42. PubMed ID: 18973137
[TBL] [Abstract][Full Text] [Related]
10. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors.
Kanazawa T; Iwashita T; Kommareddi P; Nair T; Misawa K; Misawa Y; Ueda Y; Tono T; Carey TE
Oncogene; 2007 Aug; 26(39):5762-71. PubMed ID: 17384686
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
[TBL] [Abstract][Full Text] [Related]
12. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
13. GalR1, but not GalR2 or GalR3, levels are regulated by galanin signaling in the locus coeruleus through a cyclic AMP-dependent mechanism.
Hawes JJ; Brunzell DH; Wynick D; Zachariou V; Picciotto MR
J Neurochem; 2005 Jun; 93(5):1168-76. PubMed ID: 15934937
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway.
Zhang Y; Sun L; Sun Y; Chen Y; Wang X; Xu M; Chi P; Xu Z; Lu X
Exp Cell Res; 2020 Apr; 389(1):111856. PubMed ID: 31981591
[TBL] [Abstract][Full Text] [Related]
15. Coordinated Targeting of Galanin Receptors on Cholangiocytes and Hepatic Stellate Cells Ameliorates Liver Fibrosis in Multidrug Resistance Protein 2 Knockout Mice.
Petrescu AD; Grant S; Williams E; Frampton G; Parks N; Blaney H; Davies M; John R; Reinhart EH; McMillin M; DeMorrow S
Am J Pathol; 2020 Mar; 190(3):586-601. PubMed ID: 31953035
[TBL] [Abstract][Full Text] [Related]
16. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Codony-Servat J; Cuatrecasas M; Asensio E; Montironi C; Martínez-Cardús A; Marín-Aguilera M; Horndler C; Martínez-Balibrea E; Rubini M; Jares P; Reig O; Victoria I; Gaba L; Martín-Richard M; Alonso V; Escudero P; Fernández-Martos C; Feliu J; Méndez JC; Méndez M; Gallego J; Salud A; Rojo F; Castells A; Prat A; Rosell R; García-Albéniz X; Camps J; Maurel J
Br J Cancer; 2017 Dec; 117(12):1777-1786. PubMed ID: 29123263
[TBL] [Abstract][Full Text] [Related]
17. Galanin Receptors (GalR1, GalR2, and GalR3) Expression in Colorectal Cancer Tissue and Correlations to the Overall Survival and Poor Prognosis of CRC Patients.
Kiezun J; Godlewski J; Krazinski BE; Kozielec Z; Kmiec Z
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409094
[TBL] [Abstract][Full Text] [Related]
18. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
Azar MRMH; Aghazadeh H; Mohammed HN; Sara MRS; Hosseini A; Shomali N; Tamjidifar R; Tarzi S; Mansouri M; Sarand SP; Marofi F; Akbari M; Xu H; Shotorbani SS
Int Immunopharmacol; 2021 Mar; 92():107355. PubMed ID: 33429333
[TBL] [Abstract][Full Text] [Related]
19. Preferential activation by galanin 1-15 fragment of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex.
Borroto-Escuela DO; Narvaez M; Di Palma M; Calvo F; Rodriguez D; Millon C; Carlsson J; Agnati LF; Garriga P; Díaz-Cabiale Z; Fuxe K
Biochem Biophys Res Commun; 2014 Sep; 452(3):347-53. PubMed ID: 25152404
[TBL] [Abstract][Full Text] [Related]
20. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.
Liu W; Zhang Z; Zhang Y; Chen X; Guo S; Lei Y; Xu Y; Ji C; Bi Z; Wang K
Cancer Biol Ther; 2015; 16(4):511-7. PubMed ID: 25778491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
